KOREA UNITED PHARM, INC.

As of June 30, 2026, KOREA UNITED PHARM, INC. carries a market capitalization of 276.77B, placing it among publicly traded companies globally. Its enterprise value stands at 113.07B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

KOREA UNITED PHARM, INC.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, KOREA UNITED PHARM, INC. has 15.86M shares outstanding.

As of June 30, 2026, KOREA UNITED PHARM, INC. trades at a trailing price-to-earnings ratio of 3.50. The price-to-sales ratio is 0.89, and the price-to-book ratio stands at 0.56.

As of June 30, 2026, KOREA UNITED PHARM, INC. trades at an EV/EBITDA multiple of 1.86 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 2.28 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. KOREA UNITED PHARM, INC. trades at an EV/FCF ratio of 2.89, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 113.07B versus a market cap of 276.77B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, KOREA UNITED PHARM, INC. maintains a current ratio of 5.52, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.99, indicating elevated leverage, while an interest coverage ratio of 389.44 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, KOREA UNITED PHARM, INC. posted a return on equity (ROE) of 16.72, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.87 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 14.51, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.22, useful for judging operating efficiency across full business cycles. The company generates approximately 327.38M in revenue per employee across its workforce of 910.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.04 indicates how many times KOREA UNITED PHARM, INC. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, KOREA UNITED PHARM, INC. recorded 13.48B in income tax expense. That works out to an effective tax rate of 15.04, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 89.64B, leaving 76.16B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, KOREA UNITED PHARM, INC.'s stock has declined approximately 10.14% over the past 52 weeks. The 50-day moving average sits at 17,949.80, while the 200-day moving average is 18,763.65.

Over the twelve months ended June 30, 2026, KOREA UNITED PHARM, INC. generated 298.08B in revenue and converted that into 76.16B in net income, yielding earnings per share of 4,985.14. EBITDA reached 60.87B, while operating income came in at 50.15B.

As of June 30, 2026, KOREA UNITED PHARM, INC. holds 178.56B in cash and equivalents against 14.86B in total debt, resulting in a net debt position of -27.73B. Total book value stands at 497.12B, with working capital of 245.72B providing operational flexibility.

KOREA UNITED PHARM, INC. produced 83.65B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -44.60B in capital expenditures, free cash flow totaled 39.05B - equivalent to 2,556.27 per share.

Over the twelve months ended June 30, 2026, KOREA UNITED PHARM, INC. posted a gross margin of 55.10, reflecting its pricing power and cost economics. The operating margin of 16.82 and net profit margin of 25.55 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, KOREA UNITED PHARM, INC. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 14.65, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.67, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to KOREA UNITED PHARM, INC. shareholders.

KOREA UNITED PHARM, INC.'s most recent stock split took place on January 20, 2014 with a 50:51 split ratio.

As of June 30, 2026, KOREA UNITED PHARM, INC. has an Altman Z-Score of 4.80, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.